Lai CL, et al. - In this retrospective cohort study, researchers used the Taiwan National Health Insurance claims database to compare reduced-dose dabigatran, reduced-dose rivaroxaban, and warfarin in terms of efficacy and safety in individuals aged 85 years and older with atrial fibrillation (AF). They observed statistically significantly lower all-cause mortality and cardiovascular mortality among these patients who used reduced-dose dabigatran or reduced-dose rivaroxaban vs those who used warfarin. Also, an association of reduced-dose dabigatran vs warfarin with lower risk of intracranial hemorrhage was observed.